Cargando…

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report

SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huihui, Song, Tianqi, Xu, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941368/
https://www.ncbi.nlm.nih.gov/pubmed/36824291
http://dx.doi.org/10.1016/j.jtocrr.2023.100464
_version_ 1784891271581532160
author Li, Huihui
Song, Tianqi
Xu, Xiaoling
author_facet Li, Huihui
Song, Tianqi
Xu, Xiaoling
author_sort Li, Huihui
collection PubMed
description SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due to transformation to SCLC and rapidly achieved partial response after traditional etoposide combined with cisplatin therapy. In addition, we provide a fishplot that visualizes tumor evolution on the basis of next-generation sequencing, which may predict small cell transformation and facilitate early treatment.
format Online
Article
Text
id pubmed-9941368
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99413682023-02-22 ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report Li, Huihui Song, Tianqi Xu, Xiaoling JTO Clin Res Rep Case Report SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due to transformation to SCLC and rapidly achieved partial response after traditional etoposide combined with cisplatin therapy. In addition, we provide a fishplot that visualizes tumor evolution on the basis of next-generation sequencing, which may predict small cell transformation and facilitate early treatment. Elsevier 2023-01-20 /pmc/articles/PMC9941368/ /pubmed/36824291 http://dx.doi.org/10.1016/j.jtocrr.2023.100464 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Li, Huihui
Song, Tianqi
Xu, Xiaoling
ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
title ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
title_full ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
title_fullStr ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
title_full_unstemmed ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
title_short ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
title_sort alk-positive adenocarcinoma after acquired resistance to lorlatinib and transformation to sclc: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941368/
https://www.ncbi.nlm.nih.gov/pubmed/36824291
http://dx.doi.org/10.1016/j.jtocrr.2023.100464
work_keys_str_mv AT lihuihui alkpositiveadenocarcinomaafteracquiredresistancetolorlatinibandtransformationtosclcacasereport
AT songtianqi alkpositiveadenocarcinomaafteracquiredresistancetolorlatinibandtransformationtosclcacasereport
AT xuxiaoling alkpositiveadenocarcinomaafteracquiredresistancetolorlatinibandtransformationtosclcacasereport